Temporal	O
Development	O
of	O
Autonomic	B-DS
Dysfunction	I-DS
in	O
Heart	B-DS
Failure	I-DS
:	O
Effects	O
of	O
Age	O
in	O
an	O
Ovine	O
Rapid	O
-	O
pacing	O
Model	O

Decision	O
Editor	O
:	O
Rafael	O
de	O
Cabo	O
,	O
PHD	O

Heart	B-DS
failure	I-DS
(	O
HF	B-DS
)	O
is	O
predominantly	O
a	O
disease	O
of	O
older	O
adults	O
and	O
characterized	O
by	O
extensive	O
sympatho	O
-	O
vagal	O
imbalance	O
leading	O
to	O
impaired	O
reflex	O
control	O
of	O
heart	O
rate	O
(	O
HR	O
).	O

However	O
,	O
whether	O
aging	O
influences	O
the	O
development	O
or	O
extent	O
of	O
the	O
autonomic	B-DS
imbalance	I-DS
in	O
HF	B-DS
remains	O
unclear	O
.	O

To	O
address	O
this	O
,	O
we	O
used	O
an	O
ovine	O
model	O
of	O
aging	O
with	O
tachypacing	O
-	O
induced	O
HF	B-DS
to	O
determine	O
whether	O
aging	O
affects	O
the	O
chronotropic	O
and	O
inotropic	O
responses	O
to	O
autonomic	O
stimulation	O
and	O
reduction	O
in	O
heart	O
rate	O
variability	O
(	O
HRV	O
)	O
in	O
HF	B-DS
.	O

We	O
find	O
that	O
aging	O
is	O
associated	O
with	O
increased	O
cardiac	O
dimensions	O
and	O
reduced	O
contractility	O
before	O
the	O
onset	O
of	O
tachypacing	O
,	O
and	O
these	O
differences	O
persist	O
in	O
HF	B-DS
.	O

Additionally	O
,	O
the	O
chronotropic	O
response	O
to	O
β	O
-	O
adrenergic	O
stimulation	O
was	O
markedly	O
attenuated	O
in	O
HF	B-DS
,	O
and	O
this	O
occurred	O
more	O
rapidly	O
in	O
aged	O
animals	B-OG
.	O

By	O
measuring	O
HR	O
during	O
sequential	O
autonomic	O
blockade	O
,	O
our	O
data	O
are	O
consistent	O
with	O
a	O
reduced	O
parasympathetic	O
control	O
of	O
resting	O
HR	O
in	O
aging	O
,	O
with	O
young	O
HF	B-DS
animals	B-OG
having	O
an	O
attenuated	O
sympathetic	O
influence	O
on	O
HR	O
.	O

Time	O
-	O
domain	O
analyses	O
of	O
HR	O
show	O
a	O
reduction	O
in	O
HRV	O
in	O
both	O
young	O
and	O
aged	O
failing	O
animals	B-OG
,	O
although	O
HRV	O
is	O
lowest	O
in	O
aged	O
HF	B-DS
.	O

In	O
conclusion	O
,	O
aging	O
is	O
associated	O
with	O
altered	O
autonomic	O
control	O
and	O
β	O
-	O
adrenergic	O
responsiveness	O
of	O
HR	O
,	O
and	O
these	O
are	O
exacerbated	O
with	O
the	O
development	O
of	O
HF	B-DS
.	O

In	O
the	O
healthy	O
heart	O
,	O
stimulation	O
of	O
the	O
sympathetic	O
nervous	O
system	O
via	O
β	O
-	O
adrenergic	O
pathways	O
leads	O
to	O
an	O
increase	O
in	O
heart	O
rate	O
(	O
HR	O
),	O
force	O
of	O
contraction	O
,	O
and	O
rate	O
of	O
relaxation	O
.	O

In	O
general	O
,	O
opposing	O
actions	O
are	O
mediated	O
by	O
the	O
parasympathetic	O
nervous	O
system	O
,	O
with	O
vagal	O
stimulation	O
slowing	O
HR	O
and	O
decreasing	O
contractility	O
.	O

Sympatho	O
-	O
vagal	O
imbalance	O
arising	O
as	O
a	O
result	O
of	O
reduced	O
parasympathetic	O
and	O
increased	O
sympathetic	O
activity	O
is	O
a	O
well	O
-	O
characterized	O
feature	O
of	O
heart	B-DS
failure	I-DS
(	O
HF	B-DS
),	O
contributes	O
to	O
the	O
systolic	O
dysfunction	O
associated	O
with	O
HF	B-DS
,	O
and	O
increasing	O
sympatho	O
-	O
vagal	O
imbalance	O
is	O
associated	O
with	O
progression	O
towards	O
the	O
decompensated	O
state	O
(	O
1	O
,	O
2	O
).	O

For	O
example	O
,	O
the	O
increased	O
circulating	O
levels	O
of	O
catecholamines	O
and	O
thus	O
elevated	O
sympathetic	O
drive	O
in	O
HF	B-DS
lead	O
to	O
reduced	O
responsiveness	O
to	O
β	O
-	O
adrenergic	O
stimulation	O
and	O
a	O
worsening	O
of	O
clinical	O
symptoms	O
(	O
3	O
,	O
4	O
).	O

Moreover	O
,	O
targeting	O
HF	B-DS
-	O
associated	O
sympatho	O
-	O
vagal	O
imbalance	O
through	O
chronic	O
vagal	O
nerve	O
stimulation	O
appears	O
to	O
have	O
therapeutic	O
benefit	O
in	O
both	O
experimental	O
and	O
clinical	O
HF	B-DS
(	O
5	O
,	O
6	O
).	O

There	O
is	O
also	O
evidence	O
suggesting	O
that	O
aging	O
leads	O
to	O
sympatho	O
-	O
vagal	O
imbalance	O
and	O
mis	O
-	O
control	O
of	O
HR	O
with	O
impaired	O
cardiac	O
responsiveness	O
to	O
β	O
-	O
adrenergic	O
stimulation	O
noted	O
(	O
7	O
–	O
10	O
).	O

Furthermore	O
,	O
increased	O
basal	O
levels	O
of	O
circulating	O
catecholamines	O
and	O
decreased	O
β1	B-GP
-	I-GP
adrenoreceptor	I-GP
density	O
have	O
also	O
been	O
found	O
with	O
age	O
(	O
11	O
).	O

Aging	O
is	O
also	O
a	O
major	O
risk	O
factor	O
for	O
the	O
development	O
of	O
HF	B-DS
(	O
12	O
).	O

Despite	O
the	O
clear	O
age	O
dependency	O
of	O
HF	B-DS
,	O
there	O
is	O
presently	O
a	O
paucity	O
of	O
information	O
regarding	O
whether	O
alterations	O
to	O
the	O
neurohormonal	O
axis	O
that	O
occur	O
in	O
aged	O
animals	B-OG
with	O
HF	B-DS
develop	O
to	O
the	O
same	O
degree	O
,	O
or	O
with	O
the	O
same	O
time	O
dependency	O
,	O
as	O
that	O
which	O
occurs	O
in	O
young	O
animals	B-OG
with	O
HF	B-DS
.	O

These	O
gaps	O
in	O
the	O
literature	O
exist	O
primarily	O
because	O
the	O
majority	O
of	O
experimental	O
research	O
is	O
carried	O
out	O
using	O
only	O
young	O
animals	B-OG
.	O

In	O
this	O
study	O
,	O
we	O
have	O
used	O
a	O
ventricular	O
tachypacing	O
model	O
of	O
HF	B-DS
in	O
both	O
young	O
and	O
aged	O
sheep	B-OG
to	O
investigate	O
any	O
age	O
dependency	O
in	O
the	O
temporal	O
development	O
of	O
sympatho	O
-	O
vagal	O
imbalance	O
in	O
HF	B-DS
using	O
in	O
vivo	O
techniques	O
on	O
conscious	O
animals	B-OG
.	O

We	O
find	O
that	O
aging	O
is	O
associated	O
with	O
an	O
increase	O
in	O
resting	O
HR	O
,	O
reduction	O
in	O
heart	O
rate	O
variability	O
(	O
HRV	O
),	O
and	O
a	O
reduced	O
change	O
in	O
cardiac	O
contractility	O
in	O
response	O
to	O
β	O
-	O
adrenergic	O
stimulation	O
.	O

The	O
development	O
of	O
HF	B-DS
increased	O
HR	O
,	O
reduced	O
HRV	O
,	O
attenuated	O
the	O
HR	O
response	O
to	O
β	O
-	O
adrenergic	O
stimulation	O
,	O
and	O
abolished	O
vagal	O
tone	O
in	O
both	O
young	O
and	O
aged	O
sheep	B-OG
.	O

However	O
,	O
the	O
impairment	O
of	O
β	O
-	O
adrenergic	O
responsiveness	O
occurred	O
earlier	O
in	O
aged	O
sheep	B-OG
following	O
induction	O
of	O
HF	B-DS
by	O
tachypacing	O
.	O

Also	O
,	O
during	O
complete	O
pharmacologically	O
mediated	O
autonomic	O
blockade	O
,	O
the	O
intrinsic	O
HR	O
was	O
found	O
to	O
be	O
increased	O
in	O
aging	O
.	O

We	O
conclude	O
therefore	O
that	O
HF	B-DS
leads	O
to	O
reduced	O
catecholamine	O
responsiveness	O
in	O
both	O
the	O
young	O
and	O
aged	O
,	O
but	O
these	O
effects	O
develop	O
more	O
rapidly	O
in	O
the	O
aged	O
.	O

Methods	O

All	O
procedures	O
involving	O
the	O
use	O
of	O
animals	B-OG
were	O
performed	O
in	O
accordance	O
with	O
The	O
United	O
Kingdom	O
Animals	B-OG
(	O
Scientific	O
Procedures	O
)	O
Act	O
,	O
1986	O
and	O
European	O
Union	O
Directive	O
2010	O
/	O
63	O
.	O

Institutional	O
approval	O
was	O
obtained	O
from	O
The	O
University	O
of	O
Manchester	O
Animal	B-OG
Welfare	O
and	O
Ethical	O
Review	O
Board	O
.	O

Furthermore	O
,	O
the	O
study	O
accords	O
with	O
the	O
ARRIVE	O
guidelines	O
(	O
13	O
).	O

Experimental	O
Model	O
of	O
Aging	O
and	O
HF	B-DS

Female	O
Welsh	B-OG
Mountain	I-OG
sheep	I-OG
(	O
n	O
=	O
39	O
;	O
34	O
.	O
8	O
±	O
1	O
.	O
0kg	O
)	O
aged	O
either	O
18	O
months	O
(	O
young	O
,	O
n	O
=	O
23	O
)	O
or	O
8	O
years	O
or	O
older	O
(	O
aged	O
,	O
n	O
=	O
16	O
)	O
were	O
loose	O
housed	O
in	O
groups	O
of	O
4	O
–	O
5	O
,	O
fed	O
ad	O
libitum	O
hay	O
,	O
and	O
maintained	O
on	O
a	O
12	O
-	O
hour	O
light	O
,	O
dark	O
cycle	O
at	O
20	O
±	O
2	O
°	O
C	O
.	O

Animals	B-OG
were	O
anesthetized	O
with	O
isoflurane	O
(	O
1	O
%–	O
5	O
%	O
v	O
/	O
v	O
in	O
oxygen	O
),	O
and	O
preoperative	O
analgesia	O
was	O
provided	O
(	O
meloxicom	O
0	O
.	O
5mg	O
/	O
kg	O
).	O

A	O
single	O
active	O
fixation	O
bipolar	O
IS	O
-	O
1	O
endocardial	O
pacing	O
lead	O
was	O
placed	O
trans	O
-	O
venously	O
into	O
the	O
right	O
ventricle	O
and	O
secured	O
to	O
a	O
single	O
chamber	O
cardiac	O
pacemaker	O
with	O
software	O
modification	O
(	O
High	O
Rate	O
Pacing	O
Patch	O
,	O
Medtronic	O
Inc	O
).	O

To	O
induce	O
HF	B-DS
,	O
right	O
ventricular	O
tachypacing	O
was	O
initiated	O
at	O
210	O
beats	O
per	O
minute	O
(	O
bpm	O
).	O

In	O
two	O
animals	B-OG
,	O
cardiac	O
capture	O
was	O
not	O
immediately	O
consistent	O
at	O
210	O
bpm	O
;	O
we	O
therefore	O
paced	O
these	O
animals	B-OG
at	O
180	O
bpm	O
for	O
2	O
–	O
7	O
days	O
before	O
increasing	O
to	O
210	O
bpm	O
for	O
the	O
remainder	O
of	O
the	O
study	O
.	O

On	O
presentation	O
of	O
clinical	O
signs	O
of	O
HF	B-DS
(	O
lethargy	O
,	O
dyspnea	O
),	O
tachypacing	O
was	O
stopped	O
and	O
a	O
final	O
“	O
postpacing	O
”	O
set	O
of	O
in	O
vivo	O
experiments	O
performed	O
.	O

Animals	B-OG
were	O
humanely	O
killed	O
with	O
pentobarbitone	O
sodium	O
(	O
200	O
mg	O
·	O
kg	O
−	O
1	O
)	O
with	O
10	O
,	O
000	O
units	O
of	O
heparin	O
administered	O
intravenously	O
,	O
and	O
tissues	O
were	O
harvested	O
for	O
additional	O
studies	O
.	O

For	O
all	O
in	O
vivo	O
assessments	O
of	O
cardiac	O
function	O
and	O
sympatho	O
-	O
vagal	O
balance	O
following	O
initiation	O
of	O
right	O
ventricular	O
tachypacing	O
,	O
pacemakers	O
were	O
switched	O
off	O
(	O
ODO	O
)	O
for	O
15	O
minutes	O
before	O
measurements	O
were	O
taken	O
.	O

All	O
in	O
vivo	O
experiments	O
were	O
carried	O
out	O
on	O
conscious	O
,	O
nonsedated	O
,	O
and	O
gently	O
restrained	O
animals	B-OG
.	O

Echocardiography	O
and	O
Blood	O
Pressure	O
Measurements	O

Echocardiograms	O
were	O
analyzed	O
offline	O
using	O
ImageJ	O
(	O
NIH	O
,	O
USA	O
),	O
and	O
3	O
–	O
20	O
consecutive	O
cardiac	O
cycles	O
were	O
averaged	O
to	O
obtain	O
measurements	O
.	O

Left	O
ventricular	O
(	O
LV	O
)	O
end	O
diastolic	O
internal	O
diameter	O
(	O
EDID	O
),	O
end	O
systolic	O
internal	O
diameter	O
(	O
ESID	O
),	O
relative	O
wall	O
thickness	O
(	O
RWT	O
),	O
and	O
fractional	O
shortening	O
measurements	O
were	O
all	O
obtained	O
from	O
m	O
-	O
mode	O
images	O
,	O
whereas	O
the	O
fractional	O
area	O
change	O
was	O
measured	O
from	O
short	O
-	O
axis	O
images	O
as	O
we	O
have	O
described	O
previously	O
(	O
4	O
,	O
14	O
–	O
17	O
).	O

Systolic	O
and	O
diastolic	O
blood	O
pressure	O
measurements	O
were	O
recorded	O
by	O
tail	O
cuff	O
plethysmography	O
.	O

Readings	O
were	O
obtained	O
over	O
a	O
3	O
-	O
to	O
5	O
-	O
minute	O
period	O
,	O
and	O
the	O
last	O
three	O
consistent	O
values	O
were	O
averaged	O
following	O
European	O
Society	O
of	O
Hypertension	O
(	O
ESH	O
)	O
and	O
European	O
Society	O
of	O
Cardiology	O
(	O
ESC	O
)	O
guidelines	O
(	O
18	O
).	O

Measurement	O
of	O
HR	O
and	O
HRV	O

Surface	O
electrocardiograms	O
(	O
ECGs	O
)	O
were	O
recorded	O
using	O
a	O
five	O
-	O
lead	O
orthogonal	O
configuration	O
,	O
digitized	O
to	O
personal	O
computer	O
(	O
1kHz	O
),	O
and	O
the	O
RR	O
interval	O
and	O
HR	O
were	O
analyzed	O
as	O
described	O
previously	O
using	O
shape	O
recognition	O
algorithms	O
(	O
ECG	O
Auto	O
,	O
EMKA	O
France	O
)	O
(	O
17	O
).	O

Time	O
-	O
domain	O
measures	O
of	O
HRV	O
were	O
quantified	O
as	O
RR	O
interval	O
standard	O
deviation	O
(	O
RRSD	O
)	O
and	O
the	O
coefficient	O
of	O
variance	O
of	O
RRSD	O
(	O
RRSD	O
/	O
mean	O
RR	O
interval	O
).	O

Assessment	O
of	O
Temporal	O
Development	O
of	O
Sympathetic	O
Dysfunction	O

The	O
development	O
of	O
sympathetic	O
dysfunction	O
with	O
tachypacing	O
was	O
monitored	O
weekly	O
with	O
intravenous	O
infusions	O
of	O
the	O
sympathetic	O
agonist	O
dobutamine	O
(	O
5	O
–	O
40	O
µg	O
·	O
kg	O
−	O
1	O
·	O
minute	O
−	O
1	O
,	O
Claris	O
Life	O
Sciences	O
,	O
UK	O
).	O

Dobutamine	O
concentrations	O
were	O
increased	O
in	O
twofold	O
increments	O
up	O
to	O
a	O
maximum	O
of	O
40	O
μg	O
·	O
kg	O
−	O
1	O
·	O
minute	O
−	O
1	O
or	O
until	O
HR	O
exceeded	O
150	O
bpm	O
.	O

ECGs	O
were	O
recorded	O
for	O
5	O
minutes	O
at	O
each	O
dobutamine	O
dose	O
,	O
and	O
ECG	O
parameters	O
were	O
calculated	O
from	O
the	O
last	O
60	O
seconds	O
of	O
each	O
infusion	O
period	O
.	O

Animals	B-OG
were	O
allowed	O
to	O
recover	O
for	O
at	O
least	O
30	O
minutes	O
before	O
tachypacing	O
was	O
recommenced	O
.	O

To	O
assess	O
whether	O
sympathetic	O
-	O
mediated	O
enhancement	O
of	O
cardiac	O
contractility	O
was	O
altered	O
with	O
HF	B-DS
and	O
aging	O
,	O
parasternal	O
short	O
-	O
axis	O
echocardiograms	O
were	O
obtained	O
at	O
both	O
baseline	O
and	O
immediately	O
following	O
the	O
final	O
infusion	O
of	O
dobutamine	O
(	O
5	O
µg	O
·	O
kg	O
−	O
1	O
·	O
minute	O
−	O
1	O
in	O
control	O
and	O
10	O
–	O
40	O
µg	O
·	O
kg	O
−	O
1	O
·	O
minute	O
−	O
1	O
in	O
HF	B-DS
).	O

Measurements	O
were	O
obtained	O
both	O
prior	O
to	O
tachypacing	O
(	O
control	O
)	O
and	O
once	O
HF	B-DS
had	O
developed	O
.	O

Assessment	O
of	O
Parasympathetic	O
Influence	O
of	O
HR	O
and	O
HRV	O

Parasympathetic	O
function	O
in	O
aging	O
and	O
HF	B-DS
was	O
measured	O
using	O
sequential	O
sympathetic	O
(	O
0	O
.	O
5	O
mg	O
·	O
kg	O
−	O
1	O
propranolol	O
[	O
PPL	O
];	O
prepared	O
as	O
propranolol	O
hydrochloride	O
in	O
0	O
.	O
9	O
%	O
NaCl	O
solution	O
,	O
Sigma	O
-	O
Aldrich	O
,	O
UK	O
)	O
and	O
parasympathetic	O
(	O
0	O
.	O
05	O
mg	O
·	O
kg	O
−	O
1	O
atropine	O
;	O
prepared	O
as	O
atropine	O
sulfate	O
in	O
0	O
.	O
9	O
%	O
NaCl	O
solution	O
;	O
Sigma	O
-	O
Aldrich	O
)	O
blockade	O
via	O
intravenous	O
bolus	O
with	O
an	O
additional	O
0	O
.	O
05	O
mg	O
·	O
kg	O
−	O
1	O
·	O
minute	O
−	O
1	O
atropine	O
infused	O
after	O
1	O
minute	O
to	O
maintain	O
complete	O
autonomic	O
block	O
(	O
AB	O
)	O
for	O
the	O
duration	O
of	O
the	O
experiment	O
.	O

Measurements	O
were	O
obtained	O
both	O
prior	O
to	O
the	O
start	O
of	O
tachypacing	O
and	O
once	O
HF	B-DS
had	O
developed	O
.	O

To	O
determine	O
whether	O
AB	O
was	O
complete	O
,	O
HR	O
responses	O
to	O
dobutamine	O
(	O
5	O
µg	O
·	O
kg	O
−	O
1	O
·	O
minute	O
−	O
1	O
)	O
and	O
acetylcholine	O
(	O
100	O
nmol	O
·	O
min	O
−	O
1	O
;	O
prepared	O
as	O
acetylcholine	O
chloride	O
in	O
0	O
.	O
9	O
%	O
NaCl	O
;	O
Sigma	O
-	O
Aldrich	O
)	O
were	O
assessed	O
in	O
a	O
subset	O
of	O
animals	B-OG
.	O

Quantification	O
of	O
Plasma	O
Noradrenaline	O

Blood	O
samples	O
(~	O
20mL	O
)	O
were	O
collected	O
into	O
K2EDTA	O
vacutainer	O
blood	O
collection	O
tubes	O
by	O
jugular	O
venipuncture	O
.	O

Samples	O
were	O
stored	O
on	O
ice	O
prior	O
to	O
centrifugation	O
(	O
4	O
,	O
000g	O
,	O
10	O
minutes	O
),	O
and	O
plasma	O
were	O
harvested	O
and	O
stored	O
in	O
liquid	O
nitrogen	O
until	O
use	O
.	O

Plasma	O
noradrenaline	O
was	O
quantified	O
using	O
a	O
competitive	O
ELISA	O
according	O
to	O
manufacturer	O
’	O
s	O
instructions	O
(	O
Labor	O
Diagnostika	O
Nord	O
,	O
Germany	O
).	O

Statistics	O

All	O
data	O
are	O
presented	O
as	O
the	O
mean	O
±	O
SEM	O
for	O
n	O
animals	B-OG
.	O

All	O
comparisons	O
were	O
made	O
pair	O
-	O
wise	O
on	O
the	O
same	O
animal	B-OG
—	O
that	O
is	O
,	O
control	O
versus	O
HF	B-DS
as	O
well	O
as	O
before	O
and	O
during	O
drug	O
infusions	O
.	O

Differences	O
between	O
groups	O
(	O
age	O
,	O
disease	O
,	O
and	O
drug	O
treatments	O
)	O
were	O
analyzed	O
using	O
either	O
a	O
two	O
-	O
way	O
repeated	O
measures	O
analysis	O
of	O
variance	O
(	O
ANOVA	O
)	O
firstly	O
within	O
each	O
age	O
group	O
(	O
eg	O
,	O
control	O
vs	O
HF	B-DS
;	O
pre	O
and	O
post	O
drug	O
administration	O
)	O
and	O
then	O
between	O
age	O
groups	O
(	O
ie	O
,	O
young	O
control	O
vs	O
aged	O
control	O
)	O
or	O
paired	O
Student	O
’	O
s	O
t	O
test	O
(	O
autonomic	O
blockade	O
vs	O
dobutamine	O
or	O
acetylcholine	O
).	O

Data	O
that	O
were	O
not	O
normally	O
distributed	O
were	O
transformed	O
by	O
means	O
appropriate	O
to	O
the	O
spread	O
of	O
data	O
,	O
for	O
example	O
,	O
log10	O
(	O
19	O
).	O

Differences	O
were	O
considered	O
significant	O
when	O
p	O
value	O
was	O
less	O
than	O
.	O
05	O
;	O
however	O
,	O
p	O
values	O
were	O
adjusted	O
using	O
the	O
Holm	O
-	O
Sidak	O
post	O
hoc	O
test	O
for	O
multiple	O
comparisons	O
using	O
SigmaPlot	O
11	O
.	O
0	O
.	O

Correlational	O
analysis	O
was	O
performed	O
using	O
GraphPad	O
Prism	O
6	O
.	O

Results	O

Signs	O
of	O
HF	B-DS
(	O
lethargy	O
and	O
dyspnea	O
)	O
took	O
a	O
median	O
of	O
35	O
days	O
to	O
develop	O
(	O
interquartile	O
range	O
=	O
9	O
)	O
with	O
no	O
age	O
-	O
dependent	O
differences	O
in	O
the	O
duration	O
of	O
tachypacing	O
required	O
to	O
induce	O
HF	B-DS
(	O
p	O
=	O
.	O
56	O
).	O

Tachypacing	O
was	O
not	O
associated	O
with	O
any	O
instances	O
of	O
sudden	O
death	O
,	O
and	O
all	O
animals	B-OG
completed	O
the	O
study	O
with	O
none	O
being	O
excluded	O
from	O
subsequent	O
data	O
analysis	O
.	O

As	O
in	O
our	O
previous	O
studies	O
(	O
4	O
,	O
14	O
–	O
17	O
),	O
aging	O
and	O
tachypacing	O
-	O
induced	O
HF	B-DS
were	O
associated	O
with	O
increased	O
LV	O
dimensions	O
and	O
reduced	O
contractile	O
function	O
(	O
Table	O
1	O
).	O

Of	O
note	O
,	O
aging	O
by	O
itself	O
was	O
associated	O
with	O
a	O
21	O
%	O
±	O
7	O
%	O
increase	O
in	O
EDID	O
,	O
a	O
50	O
%	O
±	O
15	O
%	O
increase	O
in	O
ESID	O
,	O
and	O
a	O
15	O
%	O
±	O
4	O
%	O
decrease	O
in	O
fractional	O
shortening	O
(	O
all	O
p	O
<	O
.	O
01	O
).	O

In	O
both	O
age	O
groups	O
,	O
HF	B-DS
increased	O
(	O
p	O
<	O
.	O
001	O
)	O
EDID	O
(	O
young	O
by	O
55	O
.	O
6	O
%	O
±	O
10	O
%;	O
aged	O
by	O
34	O
.	O
8	O
%	O
±	O
6	O
%)	O
and	O
ESID	O
(	O
young	O
by	O
232	O
%	O
±	O
21	O
%;	O
aged	O
by	O
152	O
%	O
±	O
20	O
%)	O
and	O
resulted	O
in	O
a	O
reduction	O
(	O
p	O
<	O
.	O
001	O
)	O
in	O
fractional	O
shortening	O
(	O
young	O
by	O
57	O
%	O
±	O
2	O
%;	O
aged	O
by	O
59	O
%	O
±	O
3	O
%).	O

However	O
,	O
ESID	O
and	O
fractional	O
shortening	O
were	O
worst	O
in	O
the	O
aged	O
HF	B-DS
animals	B-OG
(	O
p	O
<	O
.	O
05	O
).	O

Finally	O
,	O
HF	B-DS
was	O
associated	O
with	O
a	O
decrease	O
in	O
RWT	O
(	O
p	O
<	O
.	O
001	O
;	O
young	O
by	O
51	O
%	O
±	O
5	O
%;	O
aged	O
by	O
41	O
%	O
±	O
5	O
%).	O

Systolic	O
,	O
diastolic	O
,	O
and	O
mean	O
blood	O
pressure	O
were	O
decreased	O
similarly	O
with	O
HF	B-DS
in	O
both	O
young	O
and	O
aged	O
animals	B-OG
(	O
all	O
p	O
<	O
.	O
001	O
).	O

Summary	O
of	O
Echocardiographic	O
and	O
Hemodynamic	O
Findings	O
in	O
Aging	O
and	O
Heart	B-DS
Failure	I-DS

Young	O

Aged	O

Prepaced	O

Postpaced	O

Prepaced	O

Postpaced	O

EDID	O
(	O
cm	O
)	O

2	O
.	O
61	O
±	O
0	O
.	O
10	O

3	O
.	O
91	O
±	O
0	O
.	O
07	O
***	O

3	O
.	O
15	O
±	O
0	O
.	O
15	O
**	O

4	O
.	O
13	O
±	O
0	O
.	O
10	O
†††	O

ESID	O
(	O
cm	O
)	O

0	O
.	O
92	O
±	O
0	O
.	O
06	O

2	O
.	O
82	O
±	O
0	O
.	O
10	O
***	O

1	O
.	O
38	O
±	O
0	O
.	O
11	O
**	O

3	O
.	O
17	O
±	O
0	O
.	O
12	O
†††,#	O

Fractional	O
shortening	O

0	O
.	O
67	O
±	O
0	O
.	O
02	O

0	O
.	O
29	O
±	O
0	O
.	O
02	O
***	O

0	O
.	O
57	O
±	O
0	O
.	O
02	O
***	O

0	O
.	O
23	O
±	O
0	O
.	O
02	O
†††,#	O

RWT	O

0	O
.	O
91	O
±	O
0	O
.	O
08	O

0	O
.	O
39	O
±	O
0	O
.	O
02	O
***	O

0	O
.	O
73	O
±	O
0	O
.	O
06	O
*	O

0	O
.	O
42	O
±	O
0	O
.	O
05	O
†††	O

Fractional	O
area	O
change	O

0	O
.	O
68	O
±	O
0	O
.	O
02	O

0	O
.	O
38	O
±	O
0	O
.	O
02	O
***	O

0	O
.	O
63	O
±	O
0	O
.	O
02	O

0	O
.	O
36	O
±	O
0	O
.	O
02	O
†††	O

Systolic	O
BP	O
(	O
mmHg	O
)	O

127	O
±	O
2	O
.	O
36	O

108	O
±	O
2	O
.	O
27	O
***	O

133	O
±	O
2	O
.	O
09	O

114	O
±	O
2	O
.	O
62	O
†††	O

Diastolic	O
BP	O
(	O
mmHg	O
)	O

79	O
±	O
2	O
.	O
0	O

67	O
±	O
1	O
.	O
64	O
***	O

84	O
±	O
2	O
.	O
29	O

71	O
±	O
2	O
.	O
36	O
†††	O

Mean	O
BP	O
(	O
mmHg	O
)	O

95	O
±	O
1	O
.	O
96	O

81	O
±	O
1	O
.	O
70	O
***	O

100	O
±	O
1	O
.	O
96	O

85	O
±	O
2	O
.	O
17	O
†††	O

Notes	O
:	O
Values	O
are	O
mean	O
±	O
SEM	O
from	O
n	O
=	O
16	O
–	O
18	O
young	O
,	O
10	O
–	O
16	O
aged	O
.	O

Fractional	O
shortening	O
was	O
calculated	O
as	O
(	O
EDID	O
−	O
ESID	O
)	O
/	O
EDID	O
.	O

RWT	O
was	O
calculated	O
as	O
(	O
2	O
×	O
diastolic	O
wall	O
thickness	O
)	O
/	O
EDID	O
.	O

Fractional	O
area	O
change	O
was	O
calculated	O
as	O
(	O
end	O
diastolic	O
area	O
−	O
end	O
systolic	O
area	O
)	O
/	O
end	O
diastolic	O
area	O
.	O

BP	O
=	O
blood	O
pressure	O
;	O
EDID	O
=	O
end	O
diastolic	O
internal	O
diameter	O
;	O
ESID	O
=	O
end	O
systolic	O
internal	O
diameter	O
;	O
RWT	O
=	O
relative	O
wall	O
thickness	O
.	O

*	O
p	O
<	O
.	O
05	O
vs	O
young	O
prepaced	O
.	O
**	O
p	O
<	O
.	O
01	O
vs	O
young	O
prepaced	O
.	O
***	O
p	O
<	O
.	O
001	O
vs	O
young	O
prepaced	O
.	O
†††	O
p	O
<	O
.	O
001	O
vs	O
old	O
prepaced	O
.	O
#	O
p	O
<	O
.	O
05	O
vs	O
young	O
postpaced	O
.	O

HR	O
,	O
HRV	O
,	O
and	O
PR	O
Interval	O
Are	O
Altered	O
in	O
the	O
Ovine	O
Model	O
of	O
Aging	O
and	O
HF	B-DS

Surface	O
five	O
-	O
lead	O
orthogonal	O
ECGs	O
were	O
measured	O
both	O
prior	O
to	O
tachypacing	O
(	O
control	O
)	O
and	O
once	O
HF	B-DS
was	O
evident	O
.	O

Representative	O
Poincaré	O
plots	O
of	O
successive	O
RR	O
intervals	O
from	O
a	O
young	O
and	O
an	O
aged	O
sheep	B-OG
are	O
shown	O
in	O
Figure	O
1A	O
.	O

Resting	O
HR	O
was	O
higher	O
in	O
aged	O
than	O
in	O
young	O
animals	B-OG
(	O
Figure	O
1B	O
.	O
young	O
,	O
105	O
±	O
4	O
bpm	O
;	O
aged	O
,	O
123	O
±	O
7	O
bpm	O
;	O
p	O
<	O
.	O
05	O
).	O

HF	B-DS
was	O
associated	O
with	O
an	O
increase	O
in	O
resting	O
HR	O
(	O
122	O
±	O
6	O
bpm	O
,	O
pacemaker	O
off	O
)	O
only	O
in	O
young	O
animals	B-OG
(	O
p	O
<	O
.	O
05	O
).	O

Changes	O
to	O
baseline	O
heart	O
rate	O
heart	O
rate	O
variability	O
and	O
PR	O
interval	O
.	O

(	O
A	O
)	O
Representative	O
Poincaré	O
plots	O
of	O
successive	O
RR	O
intervals	O
in	O
young	O
(	O
left	O
)	O
and	O
aged	O
(	O
right	O
)	O
sheep	B-OG
before	O
tachypacing	O
(	O
solid	O
black	O
circles	O
)	O
and	O
in	O
HF	B-DS
(	O
open	O
gray	O
circles	O
).	O

(	O
B	O
–	O
G	O
)	O
Summary	O
data	O
for	O
young	O
control	O
(	O
YC	O
),	O
young	O
HF	B-DS
(	O
YF	O
),	O
aged	O
control	O
(	O
OC	O
),	O
and	O
aged	O
HF	B-DS
(	O
OF	O
)	O
animals	B-OG
showing	O
(	O
B	O
)	O
mean	O
HR	O
,	O
(	O
C	O
)	O
RR	O
standard	O
deviation	O
(	O
RRSD	O
),	O
(	O
D	O
)	O
coefficient	O
of	O
variance	O
of	O
RRSD	O
,	O
(	O
E	O
)	O
instantaneous	O
beat	O
-	O
to	O
-	O
beat	O
HRV	O
(	O
SD1	O
),	O
(	O
F	O
)	O
long	O
-	O
term	O
beat	O
-	O
to	O
-	O
beat	O
HRV	O
(	O
SD2	O
),	O
and	O
(	O
G	O
)	O
ratio	O
of	O
short	O
-	O
to	O
long	O
-	O
term	O
beat	O
-	O
to	O
-	O
beat	O
HRV	O
(	O
SD1	O
:	O
SD2	O
).	O

(	O
H	O
)	O
Mean	O
values	O
of	O
RRSD	O
as	O
a	O
function	O
of	O
RR	O
interval	O
.	O

The	O
solid	O
line	O
through	O
the	O
data	O
is	O
a	O
best	O
-	O
fit	O
regression	O
of	O
the	O
form	O
y	O
=	O
A	O
+	O
B	O
·	O
eC	O
forced	O
through	O
the	O
origin	O
and	O
having	O
exponent	O
(	O
C	O
)	O
of	O
2	O
.	O
355	O
.	O

(	O
I	O
).	O
Natural	O
log	O
RRSD	O
as	O
a	O
function	O
of	O
mean	O
RR	O
interval	O
with	O
the	O
solid	O
line	O
representing	O
a	O
linear	O
regression	O
to	O
the	O
data	O
(	O
p	O
<	O
.	O
001	O
).	O

In	O
panels	O
(	O
H	O
)	O
and	O
(	O
I	O
)	O
symbols	O
denote	O
:	O
○,	O
YC	O
;	O
●,	O
YF	O
;	O
□,	O
OC	O
;	O
and	O
■,	O
OF	O
.	O

(	O
J	O
)	O
PR	O
interval	O
summary	O
data	O
.	O
*	O
p	O
<	O
.	O
05	O
vs	O
YC	O
;	O
**	O
p	O
<	O
.	O
01	O
vs	O
YC	O
;	O
***	O
p	O
<	O
.	O
001	O
vs	O
YC	O
;	O
#	O
p	O
<	O
.	O
05	O
vs	O
OC	O
;	O
##	O
p	O
<	O
.	O
01	O
vs	O
OC	O
;	O
###	O
p	O
<	O
.	O
001	O
vs	O
OC	O
;	O
$	O
p	O
<	O
.	O
05	O
vs	O
YF	O
;	O
$$	O
p	O
<	O
.	O
01	O
vs	O
YF	O
.	O
n	O
=	O
13	O
–	O
18	O
young	O
,	O
9	O
–	O
11	O
aged	O
.	O

HRV	O
measured	O
in	O
the	O
time	O
domain	O
as	O
the	O
RRSD	O
(	O
Figure	O
1C	O
)	O
decreased	O
with	O
the	O
development	O
of	O
HF	B-DS
in	O
both	O
age	O
groups	O
(	O
young	O
:	O
control	O
,	O
45	O
±	O
6ms	O
;	O
HF	B-DS
,	O
29	O
±	O
5ms	O
;	O
p	O
<	O
.	O
01	O
;	O
aged	O
:	O
control	O
,	O
29	O
±	O
3ms	O
;	O
HF	B-DS
,	O
15	O
±	O
2ms	O
;	O
p	O
<	O
.	O
01	O
).	O

However	O
,	O
although	O
the	O
observed	O
differences	O
in	O
HRV	O
(	O
RRSD	O
)	O
did	O
not	O
reach	O
significance	O
in	O
aged	O
control	O
animals	B-OG
compared	O
with	O
young	O
control	O
animals	B-OG
(	O
p	O
=	O
.	O
094	O
),	O
it	O
was	O
less	O
in	O
aged	O
failing	O
compared	O
with	O
the	O
young	O
failing	O
sheep	B-OG
(	O
p	O
<	O
.	O
01	O
)	O
and	O
decreased	O
overall	O
with	O
age	O
(	O
control	O
and	O
HF	B-DS
)	O
compared	O
with	O
young	O
(	O
two	O
-	O
way	O
ANOVA	O
;	O
p	O
<	O
.	O
05	O
)	O

Time	O
-	O
domain	O
measures	O
of	O
HRV	O
such	O
as	O
RRSD	O
are	O
influenced	O
by	O
the	O
underlying	O
HR	O
(	O
20	O
–	O
22	O
),	O
and	O
we	O
also	O
see	O
a	O
strong	O
correlation	O
between	O
RRSD	O
and	O
RR	O
interval	O
in	O
sheep	B-OG
(	O
Figure	O
1H	O
–	O
I	O
;	O
p	O
<	O
.	O
001	O
).	O

We	O
have	O
therefore	O
corrected	O
for	O
the	O
age	O
and	O
HF	B-DS
-	O
dependent	O
changes	O
in	O
HR	O
by	O
normalizing	O
the	O
RRSD	O
values	O
to	O
the	O
mean	O
RR	O
interval	O
in	O
each	O
animal	B-OG
(	O
Figure	O
1D	O
).	O

We	O
find	O
that	O
the	O
coefficient	O
of	O
variance	O
of	O
the	O
RRSD	O
(	O
20	O
,	O
21	O
)	O
indicates	O
that	O
the	O
reduction	O
in	O
HRV	O
in	O
HF	B-DS
is	O
not	O
simply	O
due	O
to	O
the	O
increased	O
HR	O
(	O
young	O
:	O
control	O
,	O
0	O
.	O
074	O
±	O
0	O
.	O
009	O
;	O
HF	B-DS
,	O
0	O
.	O
054	O
±	O
0	O
.	O
009	O
;	O
p	O
<	O
.	O
05	O
;	O
Aged	O
:	O
control	O
,	O
0	O
.	O
057	O
±	O
0	O
.	O
006	O
;	O
HF	B-DS
,	O
0	O
.	O
031	O
±	O
0	O
.	O
005	O
;	O
p	O
<	O
.	O
001	O
).	O

Both	O
measures	O
therefore	O
indicate	O
a	O
reduction	O
of	O
HRV	O
in	O
both	O
young	O
and	O
aged	O
animals	B-OG
with	O
the	O
development	O
of	O
HF	B-DS
.	O

Furthermore	O
,	O
the	O
coefficient	O
of	O
variance	O
of	O
RRSD	O
was	O
decreased	O
overall	O
in	O
control	O
and	O
HF	B-DS
aged	O
animals	B-OG
(	O
two	O
-	O
way	O
ANOVA	O
,	O
p	O
<	O
.	O
05	O
)	O

The	O
final	O
way	O
in	O
which	O
we	O
have	O
assessed	O
HRV	O
in	O
aging	O
and	O
HF	B-DS
is	O
from	O
the	O
short	O
-	O
term	O
(	O
SD1	O
),	O
long	O
-	O
term	O
(	O
SD2	O
),	O
and	O
ratio	O
of	O
short	O
-	O
to	O
long	O
-	O
term	O
variation	O
of	O
successive	O
RR	O
intervals	O
obtained	O
from	O
the	O
Poincaré	O
plots	O
(	O
SD1	O
:	O
SD2	O
;	O
Figure	O
1E	O
–	O
G	O
).	O

Agreement	O
with	O
the	O
previous	O
assessments	O
of	O
HRV	O
,	O
these	O
measures	O
also	O
show	O
a	O
decrease	O
in	O
HRV	O
with	O
age	O
and	O
HF	B-DS
,	O
with	O
the	O
HF	B-DS
-	O
dependent	O
decrease	O
in	O
SD1	O
:	O
SD2	O
ratio	O
indicative	O
of	O
loss	O
of	O
parasympathetic	O
influence	O
on	O
HR	O
control	O
being	O
noted	O
in	O
both	O
age	O
groups	O
.	O

In	O
order	O
to	O
investigate	O
whether	O
conduction	O
remodeling	O
occurs	O
in	O
this	O
model	O
of	O
HF	B-DS
,	O
we	O
quantified	O
PR	O
interval	O
from	O
the	O
ECGs	O
(	O
Figure	O
1J	O
).	O

HF	B-DS
was	O
associated	O
with	O
an	O
increase	O
in	O
PR	O
interval	O
in	O
both	O
young	O
(	O
128	O
.	O
6	O
±	O
3	O
.	O
3ms	O
vs	O
95	O
.	O
9	O
±	O
3	O
.	O
2ms	O
)	O
and	O
aged	O
(	O
126	O
.	O
7	O
±	O
4	O
.	O
8ms	O
vs	O
102	O
.	O
6	O
±	O
3	O
.	O
8ms	O
)	O
sheep	B-OG
(	O
both	O
p	O
<	O
.	O
001	O
).	O

However	O
,	O
no	O
difference	O
in	O
PR	O
interval	O
was	O
detected	O
as	O
a	O
result	O
of	O
age	O
(	O
p	O
=	O
.	O
57	O
by	O
two	O
-	O
way	O
repeated	O
measures	O
ANOVA	O
).	O

Attenuated	O
Chronotropic	O
Responsiveness	O
to	O
β	O
-	O
Adrenergic	O
Stimulation	O
Occurs	O
Early	O
in	O
the	O
Development	O
of	O
HF	B-DS
by	O
Tachypacing	O
:	O
An	O
Effect	O
Accelerated	O
by	O
Aging	O

We	O
next	O
sought	O
to	O
determine	O
the	O
time	O
course	O
of	O
development	O
and	O
extent	O
of	O
sympathetic	O
dysfunction	O
in	O
aging	O
and	O
with	O
the	O
onset	O
of	O
HF	B-DS
.	O

This	O
was	O
assessed	O
weekly	O
by	O
determining	O
the	O
HR	O
responses	O
to	O
dobutamine	O
(	O
5	O
–	O
40	O
µg	O
·	O
kg	O
−	O
1	O
·	O
minute	O
−	O
1	O
,	O
Figure	O
2A	O
).	O

Before	O
the	O
onset	O
of	O
tachypacing	O
to	O
induce	O
HF	B-DS
,	O
dobutamine	O
(	O
5	O
µg	O
·	O
kg	O
−	O
1	O
·	O
minute	O
−	O
1	O
)	O
increased	O
HR	O
in	O
both	O
young	O
and	O
aged	O
animals	B-OG
by	O
63	O
%	O
±	O
14	O
%	O
in	O
young	O
and	O
42	O
%	O
±	O
14	O
%	O
in	O
aged	O
(	O
Figure	O
2B	O
and	O
C	O
;	O
p	O
<	O
.	O
001	O
vs	O
pre	O
-	O
dobutamine	O
;	O
p	O
=	O
.	O
148	O
between	O
age	O
groups	O
).	O

Although	O
this	O
dose	O
of	O
dobutamine	O
was	O
still	O
sufficient	O
to	O
increase	O
HR	O
compared	O
with	O
baseline	O
after	O
1	O
week	O
(	O
p	O
<	O
.	O
01	O
)	O
and	O
3	O
weeks	O
(	O
p	O
<	O
.	O
05	O
)	O
tachypacing	O
in	O
the	O
young	O
,	O
this	O
was	O
not	O
the	O
case	O
for	O
aged	O
animals	B-OG
where	O
,	O
after	O
just	O
1	O
week	O
of	O
tachypacing	O
,	O
no	O
change	O
in	O
HR	O
was	O
observed	O
in	O
response	O
to	O
5	O
μg	O
·	O
kg	O
−	O
1	O
·	O
minute	O
−	O
1	O
dobutamine	O
.	O

We	O
also	O
noted	O
that	O
although	O
there	O
was	O
a	O
robust	O
increase	O
in	O
HR	O
in	O
response	O
to	O
5	O
μg	O
·	O
kg	O
−	O
1	O
·	O
minute	O
−	O
1	O
dobutamine	O
in	O
both	O
young	O
and	O
aged	O
animals	B-OG
prior	O
to	O
commencement	O
of	O
tachypacing	O
,	O
at	O
the	O
onset	O
of	O
HF	B-DS
,	O
we	O
found	O
no	O
change	O
in	O
HR	O
response	O
to	O
doses	O
of	O
dobutamine	O
less	O
than	O
20	O
μg	O
·	O
kg	O
−	O
1	O
·	O
minute	O
−	O
1	O
(	O
Figure	O
2D	O
);	O
thus	O
,	O
the	O
chronotropic	O
response	O
to	O
β	O
-	O
adrenergic	O
stimulation	O
is	O
reduced	O
in	O
HF	B-DS
in	O
both	O
age	O
groups	O
although	O
appears	O
to	O
occur	O
earlier	O
in	O
the	O
aged	O
animals	B-OG
.	O

Temporal	O
development	O
of	O
sympathetic	O
dysfunction	O
in	O
heart	B-DS
failure	I-DS
and	O
aging	O
.	O

(	O
A	O
)	O
Timeline	O
of	O
experimental	O
protocol	O
used	O
to	O
assess	O
loss	O
of	O
sympathetic	O
responsiveness	O
in	O
HF	B-DS
.	O

White	O
boxes	O
indicate	O
where	O
ECGs	O
were	O
analyzed	O
.	O

(	O
B	O
,	O
C	O
)	O
Summary	O
data	O
showing	O
mean	O
HR	O
from	O
animals	B-OG
at	O
baseline	O
(	O
open	O
circles	O
)	O
and	O
in	O
response	O
to	O
intravenous	O
infusion	O
of	O
5	O
μg	O
·	O
kg	O
−	O
1	O
·	O
minute	O
−	O
1	O
dobutamine	O
(	O
DOB	O
,	O
solid	O
circles	O
)	O
in	O
(	O
B	O
)	O
young	O
and	O
(	O
C	O
)	O
aged	O
sheep	B-OG
.	O
*	O
p	O
<	O
.	O
05	O
;	O
**	O
p	O
<	O
.	O
01	O
;	O
***	O
p	O
<	O
.	O
001	O
vs	O
baseline	O
.	O

(	O
D	O
)	O
Summary	O
data	O
showing	O
HR	O
normalized	O
to	O
predobutamine	O
infusion	O
HR	O
in	O
young	O
prepaced	O
(	O
open	O
bar	O
),	O
aged	O
prepaced	O
(	O
solid	O
bar	O
),	O
young	O
HF	B-DS
(	O
striped	O
bar	O
),	O
and	O
aged	O
HF	B-DS
(	O
checked	O
bar	O
).	O
**	O
p	O
<	O
.	O
01	O
vs	O
normalized	O
resting	O
HR	O
(	O
ie	O
,	O
1	O
);	O
***	O
p	O
<	O
.	O
001	O
vs	O
pre	O
-	O
DOB	O
infusion	O
HR	O
.	O

(	O
E	O
)	O
LV	O
contractility	O
measured	O
by	O
fractional	O
area	O
change	O
throughout	O
the	O
course	O
of	O
the	O
rapid	O
-	O
pacing	O
protocol	O
in	O
young	O
(	O
solid	O
)	O
and	O
aged	O
(	O
open	O
)	O
sheep	B-OG
.	O

Two	O
-	O
way	O
repeated	O
measures	O
ANOVA	O
detected	O
a	O
significant	O
difference	O
between	O
fractional	O
area	O
change	O
and	O
weeks	O
pacing	O
(	O
p	O
<	O
.	O
001	O
).	O

(	O
F	O
,	O
G	O
).	O

LV	O
contractile	O
function	O
was	O
assessed	O
using	O
2D	O
short	O
-	O
axis	O
echocardiograms	O
.	O

Histograms	O
showing	O
summary	O
data	O
for	O
mean	O
fractional	O
area	O
change	O
pre	O
(−)	O
and	O
post	O
(+)	O
intravenous	O
dobutamine	O
(	O
DOB	O
)	O
infusion	O
in	O
(	O
F	O
)	O
young	O
,	O
(	O
G	O
)	O
aged	O
,	O
control	O
,	O
and	O
HF	B-DS
animals	B-OG
as	O
indicated	O
.	O
**	O
p	O
<	O
.	O
01	O
vs	O
Control	O
pre	O
-	O
DOB	O
;	O
***	O
p	O
<	O
.	O
001	O
vs	O
Control	O
pre	O
-	O
DOB	O
;	O
#	O
p	O
<	O
.	O
05	O
vs	O
HF	B-DS
pre	O
-	O
DOB	O
;	O
$	O
p	O
<	O
.	O
05	O
vs	O
Control	O
post	O
-	O
DOB	O
;	O
$$$	O
p	O
<	O
.	O
001	O
vs	O
Control	O
post	O
-	O
DOB	O
.	O

(	O
H	O
)	O
Summary	O
data	O
showing	O
plasma	O
noradrenaline	O
concentrations	O
determined	O
by	O
competitive	O
ELISA	O
.	O

YC	O
,	O
young	O
control	O
;	O
YF	O
,	O
young	O
heart	B-DS
failure	I-DS
;	O
OC	O
,	O
aged	O
control	O
;	O
OF	O
,	O
aged	O
heart	B-DS
failure	I-DS
.	O
#	O
p	O
<	O
.	O
05	O
vs	O
OC	O
.	O

For	O
panels	O
(	O
A	O
–	O
D	O
)	O
and	O
(	O
F	O
,	O
G	O
),	O
n	O
=	O
5	O
young	O
,	O
5	O
aged	O
,	O
for	O
panel	O
(	O
E	O
)	O
n	O
=	O
7	O
young	O
,	O
5	O
aged	O
,	O
and	O
for	O
panel	O
(	O
H	O
),	O
n	O
=	O
9	O
young	O
,	O
7	O
aged	O
.	O

Sympathetic	O
-	O
mediated	O
Inotropic	O
Function	O
Is	O
Attenuated	O
With	O
Aging	O
and	O
HF	B-DS

We	O
next	O
assessed	O
whether	O
the	O
inotropic	O
response	O
to	O
β	O
-	O
adrenergic	O
stimulation	O
,	O
assessed	O
as	O
LV	O
fractional	O
area	O
change	O
,	O
is	O
attenuated	O
in	O
aging	O
and	O
with	O
the	O
development	O
of	O
HF	B-DS
(	O
Figure	O
2E	O
–	O
G	O
).	O

In	O
both	O
young	O
and	O
aged	O
animals	B-OG
,	O
cardiac	O
contractility	O
(	O
fractional	O
area	O
change	O
)	O
decreased	O
with	O
the	O
development	O
of	O
HF	B-DS
with	O
no	O
age	O
-	O
dependent	O
temporal	O
differences	O
observed	O
(	O
Figure	O
2E	O
).	O

In	O
young	O
prepaced	O
animals	B-OG
,	O
5	O
μg	O
·	O
kg	O
−	O
1	O
·	O
minute	O
−	O
1	O
dobutamine	O
increased	O
fractional	O
area	O
change	O
by	O
31	O
%	O
±	O
10	O
%,	O
whereas	O
in	O
aged	O
control	O
animals	B-OG
,	O
this	O
dose	O
of	O
dobutamine	O
,	O
despite	O
its	O
effect	O
on	O
HR	O
,	O
did	O
not	O
increase	O
LV	O
contractility	O
significantly	O
from	O
baseline	O
(	O
p	O
=	O
.	O
129	O
).	O

On	O
development	O
of	O
HF	B-DS
,	O
the	O
contractility	O
response	O
to	O
catecholamine	O
stimulation	O
was	O
assessed	O
with	O
an	O
elevated	O
dose	O
of	O
dobutamine	O
which	O
led	O
to	O
an	O
increase	O
of	O
HR	O
to	O
150	O
bpm	O
(“	O
the	O
effective	O
dose	O
”;	O
20	O
µg	O
·	O
kg	O
−	O
1	O
·	O
minute	O
−	O
1	O
in	O
8	O
of	O
10	O
animals	B-OG
;	O
range	O
10	O
–	O
40	O
µg	O
·	O
kg	O
−	O
1	O
·	O
minute	O
−	O
1	O
).	O

In	O
young	O
HF	B-DS
animals	B-OG
,	O
the	O
effective	O
dose	O
of	O
dobutamine	O
(	O
10	O
–	O
40	O
µg	O
·	O
kg	O
−	O
1	O
·	O
minute	O
−	O
1	O
)	O
increased	O
contractility	O
by	O
31	O
%	O
±	O
13	O
%	O
(	O
p	O
<	O
.	O
05	O
)	O
and	O
in	O
aged	O
HF	B-DS
sheep	B-OG
,	O
the	O
effective	O
dose	O
of	O
dobutamine	O
(	O
20	O
µg	O
·	O
kg	O
−	O
1	O
·	O
minute	O
−	O
1	O
)	O
increased	O
fractional	O
area	O
change	O
by	O
29	O
%	O
±	O
15	O
%	O
(	O
p	O
<	O
.	O
05	O
).	O

In	O
both	O
young	O
and	O
aged	O
HF	B-DS
animals	B-OG
,	O
despite	O
the	O
increased	O
doses	O
of	O
dobutamine	O
,	O
the	O
fractional	O
area	O
changes	O
were	O
considerably	O
less	O
than	O
the	O
5	O
µg	O
·	O
kg	O
−	O
1	O
·	O
minute	O
−	O
1	O
dobutamine	O
responses	O
observed	O
before	O
tachypacing	O
commenced	O
(	O
p	O
<	O
.	O
05	O
).	O

The	O
attenuated	O
chronotropic	O
and	O
inotropic	O
responses	O
to	O
dobutamine	O
in	O
HF	B-DS
were	O
also	O
associated	O
with	O
a	O
significant	O
interaction	O
between	O
HF	B-DS
and	O
plasma	O
noradrenaline	O
levels	O
increasing	O
(	O
Figure	O
2H	O
;	O
p	O
<	O
.	O
05	O
;	O
two	O
-	O
way	O
RM	O
-	O
ANOVA	O
)	O
with	O
a	O
directly	O
observed	O
increase	O
in	O
the	O
aged	O
cohort	O
(	O
aged	O
control	O
,	O
557	O
±	O
73	O
pg	O
·	O
mL	O
−	O
1	O
;	O
aged	O
HF	B-DS
,	O
1973	O
±	O
937	O
pg	O
·	O
mL	O
−	O
1	O
;	O
p	O
<	O
.	O
05	O
).	O

Parasympathetic	O
Control	O
of	O
HR	O
Is	O
Lost	O
With	O
HF	B-DS
in	O
Both	O
Young	O
and	O
Aged	O
Animals	B-OG

Assessment	O
of	O
parasympathetic	O
control	O
of	O
HR	O
and	O
HRV	O
was	O
made	O
by	O
sequentially	O
blocking	O
sympathetic	O
and	O
parasympathetic	O
input	O
with	O
PPL	O
and	O
atropine	O
,	O
respectively	O
,	O
to	O
achieve	O
full	O
autonomic	O
blockade	O
(	O
AB	O
,	O
Figure	O
3A	O
).	O

Heart	B-DS
failure	I-DS
and	O
aging	O
mediated	O
parasympathetic	O
dysfunction	O
revealed	O
by	O
sequential	O
autonomic	O
blockade	O
.	O

(	O
A	O
)	O
Schematic	O
representation	O
of	O
experimental	O
approach	O
to	O
achieve	O
sympathetic	O
and	O
full	O
autonomic	O
blockade	O
(	O
AB	O
).	O

The	O
white	O
boxes	O
indicate	O
time	O
periods	O
used	O
to	O
analyze	O
data	O
.	O

The	O
horizontal	O
break	O
indicates	O
assessment	O
of	O
responsiveness	O
to	O
dobutamine	O
(	O
DOB	O
)	O
or	O
acetylcholine	O
(	O
ACh	O
)	O
following	O
autonomic	O
blockade	O
performed	O
in	O
a	O
subset	O
of	O
animals	B-OG
.	O

(	O
B	O
)	O
Summary	O
data	O
showing	O
(	O
upper	O
panel	O
)	O
measured	O
HR	O
predrug	O
administration	O
(	O
control	O
,	O
Con	O
),	O
after	O
intravenous	O
bolus	O
of	O
propranolol	O
(	O
PPL	O
)	O
and	O
atropine	O
(	O
AB	O
,	O
full	O
autonomic	O
block	O
)	O
obtained	O
prepacing	O
(	O
open	O
symbols	O
)	O
and	O
HF	B-DS
(	O
closed	O
symbols	O
)	O
in	O
young	O
animals	B-OG
and	O
,	O
(	O
lower	O
panel	O
)	O
tabulated	O
significance	O
values	O
.	O

(	O
C	O
)	O
Summary	O
data	O
(	O
upper	O
panel	O
)	O
and	O
tabulated	O
significance	O
data	O
(	O
lower	O
panel	O
)	O
for	O
aged	O
animals	B-OG
(	O
triangles	O
,	O
right	O
).	O
n	O
=	O
13	O
young	O
,	O
11	O
aged	O
.	O

(	O
D	O
)	O
Mean	O
intrinsic	O
HR	O
in	O
aging	O
and	O
HF	B-DS
.	O
*	O
p	O
<	O
.	O
05	O
vs	O
YC	O
;	O
***	O
p	O
<	O
.	O
001	O
vs	O
YC	O
;	O
###	O
p	O
<	O
.	O
001	O
vs	O
OC	O
.	O
n	O
=	O
13	O
YC	O
,	O
13	O
YF	O
,	O
15	O
OC	O
,	O
11	O
OF	O
.	O

(	O
E	O
,	O
F	O
).	O

Absence	O
of	O
heart	O
rate	O
responses	O
to	O
dobutamine	O
infusion	O
(	O
E	O
)	O
or	O
acetylcholine	O
(	O
F	O
)	O
following	O
autonomic	O
blockade	O
(	O
AB	O
).	O

NS	O
,	O
not	O
significant	O
.	O
n	O
=	O
4	O
each	O
group	O
.	O

In	O
young	O
prepaced	O
animals	B-OG
(	O
Figure	O
3B	O
),	O
β	B-GP
-	I-GP
adrenergic	I-GP
receptor	I-GP
antagonism	O
with	O
PPL	O
decreased	O
HR	O
by	O
29	O
%	O
±	O
6	O
%	O
(	O
p	O
<	O
.	O
001	O
)	O
and	O
subsequent	O
full	O
autonomic	O
blockade	O
led	O
to	O
a	O
60	O
%	O
±	O
12	O
%	O
increase	O
in	O
HR	O
(	O
p	O
<	O
.	O
001	O
,	O
compared	O
with	O
PPL	O
).	O

The	O
mean	O
intrinsic	O
HR	O
(	O
ie	O
,	O
outwith	O
autonomic	O
influence	O
)	O
of	O
young	O
prepaced	O
animals	B-OG
was	O
13	O
%	O
±	O
7	O
%	O
faster	O
than	O
the	O
resting	O
HR	O
(	O
predrug	O
administration	O
;	O
p	O
<	O
.	O
05	O
).	O

In	O
young	O
HF	B-DS
animals	B-OG
,	O
PPL	O
still	O
decreased	O
HR	O
(	O
by	O
20	O
%	O
±	O
6	O
%,	O
p	O
<	O
.	O
001	O
).	O

However	O
,	O
this	O
was	O
a	O
smaller	O
reduction	O
in	O
HR	O
than	O
that	O
seen	O
before	O
tachypacing	O
commenced	O
(	O
p	O
<	O
.	O
01	O
),	O
suggesting	O
reduced	O
sympathetic	O
influence	O
in	O
HF	B-DS
.	O

Furthermore	O
,	O
in	O
the	O
young	O
HF	B-DS
animals	B-OG
,	O
subsequent	O
autonomic	O
blockade	O
failed	O
to	O
have	O
any	O
additional	O
effect	O
on	O
HR	O
(	O
p	O
=	O
.	O
955	O
)	O
indicating	O
the	O
loss	O
of	O
parasympathetic	O
influence	O
on	O
HR	O
control	O
.	O

A	O
broadly	O
similar	O
pattern	O
was	O
observed	O
within	O
the	O
aged	O
group	O
(	O
Figure	O
3C	O
),	O
with	O
PPL	O
slowing	O
HR	O
by	O
31	O
%	O
±	O
6	O
%	O
compared	O
with	O
control	O
conditions	O
(	O
p	O
<	O
.	O
001	O
)	O
and	O
autonomic	O
blockade	O
increasing	O
HR	O
by	O
53	O
%	O
±	O
11	O
%	O
compared	O
with	O
PPL	O
(	O
p	O
<	O
.	O
001	O
).	O

However	O
,	O
unlike	O
in	O
the	O
young	O
control	O
animals	B-OG
,	O
the	O
intrinsic	O
HR	O
of	O
aged	O
control	O
animals	B-OG
,	O
that	O
is	O
,	O
during	O
autonomic	O
blockade	O
,	O
was	O
not	O
different	O
to	O
the	O
aged	O
control	O
resting	O
HR	O
(	O
p	O
=	O
.	O
316	O
).	O

Furthermore	O
,	O
the	O
intrinsic	O
HR	O
in	O
aged	O
control	O
animals	B-OG
is	O
greater	O
than	O
that	O
in	O
young	O
control	O
animals	B-OG
(	O
young	O
,	O
120	O
.	O
1	O
±	O
4	O
.	O
1	O
bpm	O
;	O
aged	O
130	O
.	O
8	O
±	O
3	O
.	O
0	O
bpm	O
.	O
Figure	O
3D	O
,	O
p	O
<	O
.	O
05	O
).	O

In	O
aged	O
failing	O
animals	B-OG
,	O
PPL	O
again	O
slowed	O
HR	O
(	O
by	O
29	O
%	O
±	O
4	O
%),	O
but	O
this	O
was	O
to	O
a	O
similar	O
extent	O
to	O
that	O
seen	O
in	O
the	O
prepacing	O
situation	O
(	O
p	O
=	O
.	O
154	O
).	O

In	O
aged	O
HF	B-DS
animals	B-OG
,	O
autonomic	O
blockade	O
failed	O
to	O
increase	O
HR	O
following	O
PPL	O
administration	O
(	O
p	O
=	O
.	O
88	O
).	O

Thus	O
HF	B-DS
in	O
aged	O
animals	B-OG
was	O
associated	O
with	O
a	O
loss	O
of	O
parasympathetic	O
influence	O
on	O
HR	O
,	O
but	O
sympathetic	O
influence	O
was	O
unaltered	O
.	O

The	O
only	O
age	O
-	O
dependent	O
differences	O
in	O
HR	O
noted	O
were	O
those	O
present	O
at	O
baseline	O
(	O
ie	O
,	O
prior	O
to	O
sympathetic	O
or	O
parasympathetic	O
blockade	O
).	O

In	O
both	O
prepaced	O
and	O
postpaced	O
time	O
points	O
,	O
aged	O
sheep	B-OG
had	O
a	O
higher	O
HR	O
than	O
in	O
the	O
young	O
sheep	B-OG
(	O
both	O
p	O
<	O
.	O
05	O
).	O

Importantly	O
,	O
the	O
dosages	O
of	O
PPL	O
and	O
atropine	O
used	O
to	O
achieve	O
autonomic	O
blockade	O
were	O
effective	O
at	O
preventing	O
any	O
HR	O
responses	O
to	O
subsequent	O
doses	O
of	O
dobutamine	O
or	O
acetylcholine	O
(	O
Figure	O
3E	O
and	O
F	O
).	O

Parasympathetic	O
Control	O
of	O
HRV	O
Is	O
Lost	O
With	O
the	O
Development	O
of	O
HF	B-DS

We	O
also	O
measured	O
HRV	O
from	O
the	O
RRSD	O
/	O
RR	O
ratio	O
following	O
β	B-GP
-	I-GP
adrenergic	I-GP
receptor	I-GP
blockade	O
and	O
full	O
autonomic	O
blockade	O
in	O
young	O
(	O
Figure	O
4A	O
)	O
and	O
aged	O
(	O
Figure	O
4B	O
)	O
animals	B-OG
.	O

In	O
young	O
prepaced	O
animals	B-OG
,	O
no	O
difference	O
in	O
HRV	O
was	O
detectable	O
during	O
β	O
-	O
adrenergic	O
blockade	O
with	O
PPL	O
,	O
but	O
HRV	O
was	O
reduced	O
during	O
full	O
autonomic	O
blockade	O
(	O
control	O
,	O
0	O
.	O
067	O
±	O
0	O
.	O
007	O
;	O
PPL	O
,	O
0	O
.	O
069	O
±	O
0	O
.	O
012	O
;	O
AB	O
,	O
0	O
.	O
017	O
±	O
0	O
.	O
007	O
.	O

All	O
comparisons	O
p	O
<	O
.	O
001	O
).	O

A	O
similar	O
trend	O
in	O
HRV	O
was	O
seen	O
in	O
young	O
failing	O
animals	B-OG
following	O
sequential	O
β	O
-	O
adrenergic	O
and	O
full	O
autonomic	O
blockade	O
(	O
control	O
,	O
0	O
.	O
056	O
±	O
0	O
.	O
012	O
;	O
PPL	O
,	O
0	O
.	O
049	O
±	O
0	O
.	O
007	O
;	O
AB	O
,	O
0	O
.	O
016	O
±	O
0	O
.	O
002	O
.	O

All	O
comparisons	O
p	O
<	O
.	O
01	O
)	O
such	O
that	O
,	O
in	O
young	O
animals	B-OG
under	O
full	O
autonomic	O
blockade	O
,	O
no	O
differences	O
in	O
HRV	O
exist	O
between	O
the	O
prepaced	O
and	O
HF	B-DS
conditions	O
.	O

Aging	O
and	O
heart	B-DS
failure	I-DS
mediated	O
reductions	O
in	O
heart	O
rate	O
variability	O
.	O

(	O
A	O
)	O
Summary	O
data	O
(	O
upper	O
panels	O
)	O
showing	O
RRSD	O
covariance	O
values	O
predrug	O
administration	O
(	O
control	O
,	O
con	O
),	O
after	O
propranolol	O
(	O
PPL	O
)	O
and	O
atropine	O
(	O
full	O
autonomic	O
blockade	O
,	O
AB	O
)	O
in	O
young	O
prepaced	O
(	O
open	O
bars	O
)	O
and	O
HF	B-DS
(	O
striped	O
bars	O
)	O
and	O
(	O
lower	O
panels	O
)	O
table	O
of	O
significance	O
values	O
for	O
young	O
animals	B-OG
.	O

(	O
B	O
)	O
Data	O
(	O
upper	O
panels	O
)	O
and	O
summary	O
of	O
significance	O
(	O
lower	O
panels	O
)	O
for	O
aged	O
control	O
(	O
solid	O
bars	O
)	O
and	O
HF	B-DS
(	O
checked	O
bars	O
)	O
animals	B-OG
.	O
n	O
=	O
13	O
young	O
,	O
11	O
aged	O
.	O

As	O
with	O
the	O
young	O
prepaced	O
sheep	B-OG
,	O
no	O
difference	O
in	O
HRV	O
was	O
found	O
in	O
aged	O
prepaced	O
animals	B-OG
following	O
PPL	O
,	O
but	O
HRV	O
was	O
less	O
during	O
full	O
autonomic	O
blockade	O
(	O
control	O
,	O
0	O
.	O
051	O
±	O
0	O
.	O
004	O
;	O
PPL	O
,	O
0	O
.	O
061	O
±	O
0	O
.	O
01	O
;	O
AB	O
,	O
0	O
.	O
007	O
±	O
0	O
.	O
001	O
.	O

All	O
comparisons	O
p	O
<	O
.	O
001	O
).	O

However	O
,	O
in	O
aged	O
failing	O
animals	B-OG
,	O
neither	O
PPL	O
nor	O
full	O
autonomic	O
blockade	O
altered	O
the	O
coefficient	O
of	O
variation	O
of	O
RRSD	O
(	O
RRSD	O
/	O
mean	O
RR	O
;	O
control	O
,	O
0	O
.	O
031	O
±	O
0	O
.	O
005	O
;	O
PPL	O
,	O
0	O
.	O
025	O
±	O
0	O
.	O
004	O
;	O
AB	O
,	O
0	O
.	O
015	O
±	O
0	O
.	O
002	O
).	O

The	O
coefficient	O
of	O
variance	O
of	O
RRSD	O
measure	O
of	O
HRV	O
demonstrated	O
that	O
HRV	O
was	O
less	O
at	O
both	O
baseline	O
(	O
no	O
drug	O
infusions	O
)	O
and	O
following	O
β	O
-	O
adrenergic	O
blockade	O
in	O
aged	O
failing	O
sheep	B-OG
compared	O
with	O
the	O
prepacing	O
values	O
(	O
p	O
<	O
.	O
01	O
).	O

The	O
only	O
age	O
-	O
dependent	O
difference	O
in	O
the	O
coefficient	O
of	O
variance	O
of	O
RRSD	O
measurement	O
of	O
HRV	O
following	O
sequential	O
β	O
-	O
adrenergic	O
antagonism	O
and	O
full	O
autonomic	O
blockade	O
was	O
in	O
HF	B-DS
both	O
at	O
baseline	O
and	O
after	O
PPL	O
administration	O
.	O

Thus	O
HRV	O
was	O
less	O
in	O
aged	O
HF	B-DS
animals	B-OG
than	O
in	O
young	O
HF	B-DS
animals	B-OG
at	O
baseline	O
(	O
no	O
drug	O
infusion	O
)	O
and	O
following	O
β	B-GP
-	I-GP
adrenergic	I-GP
receptor	I-GP
antagonism	O
(	O
p	O
<	O
.	O
05	O
).	O

Following	O
full	O
autonomic	O
blockade	O
,	O
HRV	O
(	O
coefficient	O
of	O
variance	O
of	O
RRSD	O
)	O
was	O
the	O
same	O
in	O
both	O
young	O
and	O
aged	O
HF	B-DS
animals	B-OG
.	O

Discussion	O

The	O
aims	O
of	O
the	O
present	O
study	O
were	O
to	O
determine	O
whether	O
aging	O
influences	O
the	O
evolution	O
of	O
autonomic	B-DS
dysfunction	I-DS
during	O
the	O
development	O
of	O
HF	B-DS
.	O

The	O
major	O
findings	O
were	O
(	O
i	O
)	O
cardiac	O
dimensions	O
are	O
greater	O
and	O
indices	O
of	O
contractility	O
are	O
less	O
in	O
aged	O
HF	B-DS
animals	B-OG
;	O
(	O
ii	O
)	O
chronotropic	O
and	O
inotropic	O
responses	O
to	O
β	O
-	O
adrenergic	O
stimulation	O
are	O
reduced	O
in	O
both	O
aged	O
and	O
young	O
animals	B-OG
with	O
HF	B-DS
but	O
develop	O
earlier	O
in	O
the	O
progression	O
of	O
tachypacing	O
-	O
induced	O
HF	B-DS
in	O
the	O
aged	O
;	O
(	O
iii	O
)	O
time	O
-	O
domain	O
measures	O
of	O
HRV	O
are	O
reduced	O
as	O
a	O
consequence	O
of	O
HF	B-DS
in	O
both	O
young	O
and	O
aged	O
animals	B-OG
,	O
but	O
these	O
are	O
more	O
pronounced	O
in	O
the	O
aged	O
,	O
with	O
some	O
indices	O
showing	O
reduced	O
HRV	O
as	O
a	O
consequence	O
of	O
aging	O
alone	O
;	O
and	O
(	O
iv	O
)	O
following	O
sequential	O
autonomic	O
blockade	O
to	O
assess	O
the	O
sympatho	O
-	O
vagal	O
influence	O
on	O
the	O
control	O
of	O
HR	O
we	O
found	O
subtle	O
age	O
-	O
dependent	O
differences	O
in	O
HF	B-DS
,	O
although	O
before	O
tachypacing	O
commenced	O
the	O
intrinsic	O
HR	O
(	O
ie	O
,	O
during	O
full	O
autonomic	O
blockade	O
)	O
was	O
greater	O
than	O
the	O
resting	O
HR	O
in	O
young	O
animals	B-OG
.	O

Together	O
these	O
findings	O
indicate	O
that	O
there	O
are	O
subtle	O
age	O
-	O
dependent	O
effects	O
on	O
(	O
i	O
)	O
the	O
extent	O
of	O
cardiac	O
remodeling	O
,	O
(	O
ii	O
)	O
β	O
-	O
adrenergic	O
responsiveness	O
,	O
and	O
(	O
iii	O
)	O
autonomic	O
control	O
of	O
HR	O
with	O
the	O
development	O
of	O
HF	B-DS
.	O

Aging	O
is	O
known	O
to	O
influence	O
a	O
number	O
of	O
cardiac	O
physiological	O
and	O
structural	O
variables	O
including	O
the	O
occurrence	O
of	O
cardiac	B-DS
fibrosis	I-DS
(	O
17	O
,	O
23	O
,	O
24	O
),	O
mitochondrial	O
dysfunction	O
,	O
(	O
25	O
)	O
and	O
in	O
the	O
context	O
of	O
the	O
present	O
study	O
,	O
impaired	O
inotropic	O
reserve	O
and	O
exercise	O
intolerance	O
;	O
the	O
latter	O
being	O
considered	O
hallmarks	O
of	O
aging	O
(	O
8	O
).	O

The	O
opposing	O
actions	O
of	O
the	O
sympathetic	O
and	O
parasympathetic	O
innervation	O
of	O
the	O
heart	O
ultimately	O
determine	O
HR	O
and	O
contribute	O
to	O
the	O
beat	O
-	O
to	O
-	O
beat	O
variability	O
of	O
HR	O
,	O
and	O
these	O
controlling	O
factors	O
are	O
known	O
to	O
be	O
altered	O
by	O
aging	O
(	O
26	O
,	O
27	O
).	O

We	O
show	O
that	O
aging	O
also	O
influences	O
these	O
parameters	O
in	O
response	O
to	O
the	O
development	O
of	O
HF	B-DS
.	O

Specifically	O
,	O
using	O
an	O
ovine	O
model	O
of	O
aging	O
we	O
show	O
that	O
HR	O
is	O
increased	O
whereas	O
time	O
-	O
domain	O
measures	O
of	O
HRV	O
and	O
the	O
inotropic	O
response	O
to	O
β	O
-	O
adrenergic	O
stimulation	O
are	O
reduced	O
.	O

These	O
findings	O
are	O
consistent	O
with	O
a	O
diminished	O
responsiveness	O
to	O
catecholamines	O
in	O
aging	O
being	O
observed	O
at	O
the	O
cellular	O
(	O
28	O
,	O
29	O
),	O
tissue	O
(	O
8	O
),	O
and	O
whole	O
heart	O
(	O
30	O
)	O
levels	O
.	O

The	O
elevated	O
plasma	O
catecholamine	O
levels	O
noted	O
in	O
some	O
studies	O
of	O
aging	O
[(	O
31	O
,	O
32	O
);	O
Figure	O
2H	O
]	O
may	O
be	O
directly	O
contributing	O
to	O
the	O
decreased	O
inotropic	O
and	O
chronotropic	O
adrenergic	O
responsiveness	O
of	O
the	O
aged	O
heart	O
due	O
to	O
desensitization	O
and	O
internalization	O
of	O
the	O
β	B-GP
-	I-GP
adrenergic	I-GP
receptors	I-GP
as	O
has	O
been	O
previously	O
noted	O
in	O
both	O
aging	O
(	O
11	O
)	O
and	O
HF	B-DS
(	O
4	O
).	O

A	O
substantial	O
body	O
of	O
evidence	O
demonstrates	O
that	O
the	O
elevated	O
sympathetic	O
drive	O
in	O
HF	B-DS
ultimately	O
leads	O
to	O
a	O
diminished	O
myocardial	O
response	O
to	O
β	O
-	O
adrenergic	O
stimulation	O
,	O
for	O
example	O
,	O
see	O
(	O
3	O
,	O
4	O
,	O
33	O
).	O

In	O
this	O
study	O
,	O
we	O
have	O
demonstrated	O
that	O
the	O
development	O
of	O
impaired	O
β	O
-	O
adrenergic	O
responsiveness	O
occurs	O
earlier	O
in	O
aged	O
animals	B-OG
during	O
the	O
progression	O
of	O
HF	B-DS
.	O

A	O
similar	O
age	O
-	O
dependent	O
attenuation	O
of	O
β	O
-	O
adrenergic	O
influence	O
on	O
HR	O
has	O
been	O
noted	O
following	O
exercise	O
in	O
patients	O
(	O
34	O
).	O

However	O
,	O
although	O
the	O
aged	O
HF	B-DS
animals	B-OG
develop	O
impaired	O
inotropic	O
and	O
chronotropic	O
responses	O
to	O
β	O
-	O
adrenergic	O
stimulation	O
earlier	O
than	O
the	O
young	O
HF	B-DS
animals	B-OG
,	O
there	O
are	O
no	O
age	O
-	O
dependent	O
difference	O
in	O
β	O
-	O
adrenergic	O
responsiveness	O
once	O
HF	B-DS
has	O
developed	O
,	O
that	O
is	O
,	O
HF	B-DS
results	O
in	O
a	O
marked	O
attenuation	O
of	O
the	O
chronotropic	O
response	O
in	O
both	O
the	O
young	O
and	O
aged	O
.	O

Thus	O
aging	O
may	O
be	O
an	O
important	O
factor	O
determining	O
the	O
temporal	O
development	O
,	O
rather	O
than	O
ultimate	O
outcome	O
,	O
of	O
,	O
impaired	O
responsiveness	O
to	O
catecholamines	O
as	O
a	O
result	O
of	O
pathological	O
stresses	O
such	O
as	O
HF	B-DS
.	O

Although	O
we	O
were	O
unable	O
to	O
monitor	O
the	O
temporal	O
development	O
of	O
impaired	O
parasympathetic	O
influence	O
on	O
HR	O
control	O
with	O
the	O
onset	O
of	O
tachypacing	O
,	O
we	O
did	O
note	O
that	O
,	O
in	O
both	O
young	O
and	O
aged	O
animals	B-OG
,	O
there	O
was	O
a	O
marked	O
loss	O
of	O
the	O
parasympathetic	O
control	O
of	O
HR	O
once	O
HF	B-DS
had	O
developed	O
.	O

Classically	O
,	O
the	O
parasympathetic	O
influence	O
on	O
the	O
heart	O
is	O
to	O
slow	O
sinus	O
node	O
firing	O
rate	O
and	O
thus	O
HR	O
.	O

Additionally	O
,	O
the	O
parasympathetic	O
input	O
to	O
the	O
heart	O
is	O
also	O
thought	O
to	O
determine	O
the	O
short	O
-	O
term	O
variability	O
of	O
HR	O
,	O
albeit	O
as	O
a	O
saturating	O
function	O
of	O
parasympathetic	O
activity	O
(	O
35	O
,	O
36	O
).	O

The	O
increase	O
in	O
resting	O
HR	O
with	O
age	O
,	O
as	O
well	O
as	O
the	O
unaltered	O
HR	O
following	O
full	O
autonomic	O
block	O
noted	O
in	O
aged	O
animals	B-OG
,	O
suggests	O
that	O
there	O
is	O
a	O
reduced	O
parasympathetic	O
component	O
to	O
the	O
control	O
of	O
HR	O
in	O
aging	O
.	O

Moreover	O
,	O
following	O
tachypacing	O
,	O
there	O
is	O
a	O
dramatic	O
reduction	O
/	O
loss	O
of	O
parasympathetic	O
input	O
to	O
controlling	O
HR	O
in	O
both	O
age	O
groups	O
,	O
as	O
demonstrated	O
by	O
(	O
i	O
)	O
the	O
marked	O
reductions	O
in	O
several	O
time	O
-	O
domain	O
measures	O
of	O
HRV	O
and	O
(	O
ii	O
)	O
the	O
failure	O
of	O
parasympathetic	O
blockade	O
with	O
atropine	O
to	O
influence	O
HR	O
following	O
β	O
-	O
adrenergic	O
blockade	O
with	O
PPL	O
.	O

Such	O
observations	O
are	O
common	O
to	O
numerous	O
studies	O
of	O
HF	B-DS
.	O

However	O
,	O
the	O
influence	O
of	O
aging	O
on	O
this	O
response	O
has	O
been	O
less	O
well	O
characterized	O
(	O
37	O
);	O
albeit	O
that	O
,	O
at	O
least	O
in	O
the	O
present	O
study	O
,	O
aging	O
does	O
not	O
appear	O
to	O
influence	O
this	O
outcome	O
once	O
HF	B-DS
has	O
developed	O
.	O

Given	O
that	O
reduced	O
parasympathetic	O
activity	O
is	O
generally	O
held	O
to	O
indicate	O
poor	O
outcomes	O
in	O
HF	B-DS
,	O
for	O
example	O
,	O
see	O
(	O
38	O
),	O
the	O
beneficial	O
effects	O
of	O
chronic	O
vagal	O
nerve	O
stimulation	O
in	O
HF	B-DS
may	O
,	O
in	O
part	O
,	O
arise	O
from	O
the	O
improved	O
autonomic	O
control	O
of	O
HR	O
(	O
6	O
).	O

Further	O
studies	O
are	O
required	O
to	O
elucidate	O
other	O
cardioprotective	O
mechanisms	O
that	O
may	O
arise	O
from	O
vagal	O
nerve	O
stimulation	O
.	O

Study	O
Limitations	O

Although	O
the	O
tachypacing	O
approaches	O
are	O
considered	O
useful	O
models	O
of	O
dilated	B-DS
cardiomyopathy	I-DS
and	O
tachycardic	B-DS
cardiomyopathy	I-DS
(	O
39	O
),	O
they	O
do	O
not	O
replicate	O
the	O
most	O
common	O
cause	O
of	O
HF	B-DS
occurring	O
as	O
a	O
result	O
of	O
myocardial	B-DS
ischemia	I-DS
.	O

However	O
,	O
the	O
autonomic	O
perturbations	O
noted	O
in	O
the	O
sheep	B-OG
model	O
of	O
aging	O
and	O
tachypacing	O
-	O
induced	O
HF	B-DS
are	O
consistent	O
with	O
those	O
seen	O
in	O
other	O
causes	O
of	O
HF	B-DS
and	O
suggest	O
a	O
common	O
effect	O
on	O
the	O
sympatho	O
-	O
vagal	O
control	O
of	O
HR	O
independent	O
of	O
the	O
underlying	O
cause	O
of	O
this	O
condition	O
.	O

Secondly	O
,	O
we	O
did	O
not	O
perform	O
weekly	O
assessments	O
of	O
parasympathetic	O
function	O
(	O
using	O
autonomic	O
blockade	O
),	O
during	O
the	O
development	O
of	O
HF	B-DS
due	O
to	O
the	O
risk	O
of	O
arrhythmias	B-DS
once	O
tachypacing	O
was	O
resumed	O
while	O
animals	B-OG
were	O
still	O
subject	O
to	O
the	O
effects	O
of	O
circulating	O
PPL	O
and	O
atropine	O
.	O

However	O
,	O
the	O
chronotropic	O
response	O
to	O
β	O
-	O
adrenergic	O
stimulation	O
was	O
assessed	O
weekly	O
and	O
demonstrated	O
that	O
sympathetic	O
dysfunction	O
arises	O
very	O
early	O
in	O
the	O
development	O
of	O
HF	B-DS
.	O

Finally	O
,	O
due	O
to	O
the	O
orientation	O
of	O
the	O
cardiac	O
apex	O
over	O
the	O
sternum	O
,	O
we	O
were	O
unable	O
to	O
obtain	O
conventional	O
transthoracic	O
long	O
-	O
axis	O
apical	O
views	O
of	O
the	O
heart	O
by	O
echocardiography	O
and	O
are	O
therefore	O
unable	O
to	O
satisfactorily	O
determine	O
a	O
number	O
of	O
indices	O
of	O
cardiac	O
function	O
,	O
for	O
example	O
,	O
E	O
/	O
A	O
ratios	O
,	O
torsion	O
,	O
and	O
ejection	O
fraction	O
.	O

Nevertheless	O
,	O
the	O
long	O
-	O
and	O
short	O
-	O
axis	O
views	O
that	O
we	O
have	O
quantified	O
clearly	O
show	O
a	O
marked	O
deterioration	O
in	O
cardiac	O
function	O
with	O
aging	O
and	O
the	O
development	O
of	O
HF	B-DS
.	O

Conclusion	O

In	O
conclusion	O
,	O
we	O
have	O
demonstrated	O
that	O
aging	O
results	O
in	O
cardiac	O
remodeling	O
,	O
reduced	O
contractility	O
,	O
reduced	O
HRV	O
assessed	O
by	O
some	O
time	O
-	O
domain	O
analysis	O
approaches	O
,	O
and	O
reduced	O
response	O
to	O
β	O
-	O
adrenergic	O
stimulation	O
.	O

With	O
the	O
development	O
of	O
HF	B-DS
,	O
we	O
noted	O
that	O
aging	O
is	O
associated	O
with	O
a	O
more	O
rapid	O
loss	O
of	O
the	O
chronotropic	O
response	O
to	O
β	O
-	O
adrenergic	O
stimulation	O
,	O
greater	O
cardiac	O
dimensions	O
,	O
and	O
impaired	O
contractility	O
,	O
and	O
finally	O
,	O
subtle	O
changes	O
in	O
sympatho	O
-	O
vagal	O
imbalance	O
compared	O
with	O
young	O
HF	B-DS
animals	B-OG
.	O

Taken	O
together	O
,	O
given	O
the	O
age	O
dependence	O
of	O
the	O
development	O
of	O
HF	B-DS
in	O
the	O
general	O
population	O
,	O
our	O
findings	O
suggest	O
that	O
aging	O
is	O
an	O
important	O
factor	O
determining	O
the	O
development	O
and	O
extent	O
of	O
autonomic	B-DS
dysfunction	I-DS
in	O
HF	B-DS
.	O

The	O
outcomes	O
of	O
current	O
clinical	O
trials	O
targeting	O
the	O
vagal	O
nerve	O
may	O
therefore	O
be	O
influenced	O
by	O
patient	O
age	O
.	O

Conflict	O
of	O
Interest	O

None	O
.	O

